Natixis Advisors LLC Buys 17,933 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Natixis Advisors LLC boosted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 29.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,073 shares of the company's stock after buying an additional 17,933 shares during the period. Natixis Advisors LLC owned 0.23% of TransMedics Group worth $12,258,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TMDX. International Assets Investment Management LLC acquired a new position in TransMedics Group in the 2nd quarter valued at approximately $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group during the third quarter valued at about $55,000. J.Safra Asset Management Corp lifted its stake in shares of TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock valued at $67,000 after buying an additional 383 shares during the period. Signaturefd LLC raised its holdings in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after acquiring an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company's stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now directly owns 21,105 shares of the company's stock, valued at $3,714,902.10. This represents a 32.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock worth $5,230,528 in the last 90 days. 7.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TMDX. Oppenheimer dropped their price objective on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 29th. JPMorgan Chase & Co. reduced their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an "overweight" rating for the company in a research note on Tuesday, October 29th. Canaccord Genuity Group reduced their price target on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a research note on Wednesday. Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. Finally, Needham & Company LLC lowered their price objective on TransMedics Group from $208.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of "Buy" and a consensus target price of $131.80.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $76.90 on Thursday. The stock has a fifty day simple moving average of $122.08 and a two-hundred day simple moving average of $138.50. The firm has a market cap of $2.58 billion, a price-to-earnings ratio of 82.13 and a beta of 2.08. TransMedics Group, Inc. has a 1-year low of $67.77 and a 1-year high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analysts' expectations of $115.00 million. During the same period in the previous year, the firm posted ($0.12) EPS. The firm's revenue for the quarter was up 63.7% compared to the same quarter last year. Analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.